SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is surging as a nostalgic yet serious cultural movement, leveraging its 2011 origin as the internet's original Bitcoin parody to capture investor attention. The community is actively highlighting its deep historical roots, recent high-profile whale endorsements, and its transition onto modern blockchain infrastructure as key factors driving its momentum.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community leans into its established two-year Solana history, using persistent meme-driven engagement and organic social promotion to rally holders. Investors are actively discussing the token's presence on the Jupiter strict list and its role within the broader meme coin meta, with discussions centered on whale accumulation and long-term community dedication.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders actively accumulate during a consolidation phase, citing the project's unique "phygital" strategy and retail presence as key pillars for long-term growth. While some investors debate the risks of meme coin volatility, the community is heavily focused on potential breakout triggers and the project's ongoing brand expansion efforts.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is gaining significant traction as traders weigh a major expansion to the Ethereum mainnet alongside strong institutional accumulation and consistent protocol revenue growth. The community is actively discussing the token's role as a primary liquidity hub on the Base ecosystem, with many investors viewing current price action as a strategic accumulation opportunity ahead of anticipated market shifts.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as a high-volatility meme coin on the Solana network, with the community actively celebrating its early growth, developer accessibility, and airdrop events. Traders are focused on pushing the token past key market cap milestones while encouraging engagement through aggressive social media activity and strategic buying during dips.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

The TRUMP meme coin is facing severe downward pressure and community backlash, with investors reacting to allegations of a "pump and dump" scheme and frustration over the coin's utility following recent high-profile events. The conversation is dominated by intense political polarization, with critics citing the coin as part of a broader pattern of financial exploitation while supporters continue to debate its role as a speculative asset.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending as investors react to the FDA lifting clinical holds on its key cardiovascular trial, fueling speculation about a potential short squeeze given the stock's elevated short interest. While the company faces pressure from macroeconomic volatility and dilution concerns, the community is focused on the long-term potential of its in vivo gene editing pipeline and upcoming pivotal trial data readouts.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco is currently trending as investors focus on the company's central role in the nuclear energy sector, bolstered by significant federal investments in reactor buildouts and sustained long-term demand for uranium as a baseload power source for AI infrastructure. The community is actively discussing Cameco's strong institutional support and its strategic positioning within the nuclear fuel cycle while weighing the stock's recent price appreciation against long-term growth prospects.

TOSHI

TOSHI is drawing significant community attention as investors discuss technical accumulation patterns and potential deflationary catalysts from the project's AI-driven tools. The sentiment remains largely bullish, with many participants viewing the current price action as a consolidation phase before a wider meme coin market rally.

Pulse Biosciences, Inc. operates as an immuno-oncology company developing a proprietary oncolytic electroceutical therapy based on its Nano Pulse Stimulation (NPS) technology. It manufactures surgical and medical instruments using a novel and proprietary platform technology called Nano-Pulse Electro-Signaling. The NPES provides local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. The company was founded on May 19, 2014 and is headquartered in Miami, FL.

Pulse Biosciences Inc

Pulse Biosciences is trending as investors react to positive long-term clinical data for its nPulse cardiac system, fueling speculation about potential industry partnerships and a breakthrough in the atrial fibrillation market. The community is actively discussing the stock's growth potential in the PFA sector, with many participants pointing to strong insider confidence and upcoming strategic events as key catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BELLUS Health is focused on developing drugs for rare diseases, starting with conditions that affect the kidneys. The lead program KIACTAâ?¢, a novel drug candidate, is in data review after announcing on June 20, 2016 top-line results from its Phase 3 study for the treatment of AA amyloidosis, a rare disease resulting in renal dysfunction that often leads to dialysis and death. BELLUS Health is partnered with global private equity firm Auven Therapeutics for the development of KIACTAâ?¢. KIACTAâ?¢ is also being developed as a treatment in a second indication called sarcoidosis, a rare, potentially fatal inflammatory condition that affects the lungs. An investigational new drug application (IND) for a Phase 2/3 clinical study is expected to be filed with the U.S. Food and Drug Administration in 2016. In addition, BELLUS Health is developing Shigamabâ?¢, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli (sHUS). sHUS often leads to dialysis, chronic kidney disease and in some cases death, particularly in children. Shigamabâ?¢ pre-clinical studies for the treatment of sHUS are currently underway.  BELLUS Healthâ??s pipeline also includes a research-stage project for the treatment of AL amyloidosis, a rare disease in which amyloid protein builds up and causes dysfunction in various parts of the body.

BLU
Bellus Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLU News

BLUBellus Health Inc